Oral vs Transdermal Estrogen – Notes
- Topic: Oral versus transdermal estrogen (HRT) and their different effects on clotting, lipids, inflammation, and cardiovascular risk.
- The lecture argues that oral estrogen undergoes first-pass metabolism in the liver, which alters multiple proteins including clotting factors and lipoproteins, driving thrombotic risk but also affecting lipid profiles.
- Transdermal estradiol avoids the first-pass hepatic effect, purportedly reducing thrombotic risk but allegedly losing certain cardiovascular lipid benefits seen with oral estrogen.
- The speaker emphasizes that transdermal is often framed as safer for clotting risk and is labeled the current estrogen of choice by some professional bodies in lectures (ACOG, NAMS), while arguing that the lipid and anti-atherosclerotic advantages of oral estradiol are not achieved with transdermal.
- There is substantial emphasis on nuance: benefits and risks depend on form of estrogen, co-prescribed progestin, patient risk factors (hypertension, diabetes, BMI, thrombophilias), and whether the benefit on lipids/insulin sensitivity is prioritized over thrombotic risk.
- The notes below summarize the transcript’s key points, data references, and clinical implications as presented by the speaker.
- Important to distinguish author’s claims in this lecture from all guideline statements; some points reflect a particular clinical perspective and interpretation of trials.